Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-19-050606

Chief Executive Officer sold 112,650 shares at an average $28.54 ($3,215,055)

  • Chief Executive Officer acquired 112,650 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Anzalone Christopher Richard · Chief Executive Officer

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2019-09-20 Exercise or conversion : show line 1 in the form +4,250 $5.10 $21,675 2,146,153 D
2019-09-20 Sale : show line 2 in the form −4,250 $29.00 $123,250 2,141,903 D
2019-09-23 Exercise or conversion : show line 3 in the form +41,755 $5.10 $212,951 2,183,658 D
2019-09-23 Sale : show line 4 in the form −41,755 $29.04 $1,212,565 2,141,903 D
2019-09-24 Exercise or conversion : show line 5 in the form +66,645 $5.10 $339,890 2,208,548 D
2019-09-24 Sale : show line 6 in the form −53,972 $28.00 $1,511,216 2,154,576 D
2019-09-24 Sale : show line 7 in the form −12,673 $29.04 $368,024 2,141,903 D
Open-market sales · 112,650 sh · avg $28.54 · $3,215,055

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2019-09-20 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −4,250 1,110,268 D
2019-09-23 Exercise or conversion : show line 9 in the form Stock Option (right to buy) −41,755 1,068,513 D
2019-09-24 Exercise or conversion : show line 10 in the form Stock Option (right to buy) −66,645 1,001,868 D
Loading xslF345X03/doc4.xml…